StockNews.com Initiates Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX)

Equities research analysts at StockNews.com started coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research note issued on Wednesday. The brokerage set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Trading Up 7.1 %

Brooklyn ImmunoTherapeutics stock opened at $2.40 on Wednesday. The company has a market capitalization of $141.18 million, a price-to-earnings ratio of -1.06 and a beta of 4.61. The stock’s 50 day moving average is $1.98 and its 200-day moving average is $1.80. Brooklyn ImmunoTherapeutics has a 12 month low of $0.17 and a 12 month high of $10.10.

Institutional Investors Weigh In On Brooklyn ImmunoTherapeutics

An institutional investor recently raised its position in Brooklyn ImmunoTherapeutics stock. Renaissance Technologies LLC boosted its holdings in Brooklyn ImmunoTherapeutics Inc (NYSE:BTX) by 20.1% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,459,626 shares of the company’s stock after purchasing an additional 243,826 shares during the quarter. Renaissance Technologies LLC owned 2.48% of Brooklyn ImmunoTherapeutics worth $360,000 at the end of the most recent reporting period. 26.00% of the stock is currently owned by institutional investors and hedge funds.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.